Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

151 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Biophysical and Immunological Characterization and In Vivo Pharmacokinetics and Toxicology in Nonhuman Primates of the Anti-PD-1 Antibody Pembrolizumab.
Hutchins B, Starling GC, McCoy MA, Herzyk D, Poulet FM, Dulos J, Liu L, Kang SP, Fayadat-Dilman L, Hsieh M, Andrews CL, Ayanoglu G, Cullen C, Malefyt RW, Kastelein RA, Saux SL, Lee J, Li S, Malashock D, Sadekova S, Soder G, van Eenennaam H, Willingham A, Yu Y, Streuli M, Carven GJ, van Elsas A. Hutchins B, et al. Among authors: willingham a. Mol Cancer Ther. 2020 Jun;19(6):1298-1307. doi: 10.1158/1535-7163.MCT-19-0774. Epub 2020 Mar 30. Mol Cancer Ther. 2020. PMID: 32229606
Characterization of MK-4166, a Clinical Agonistic Antibody That Targets Human GITR and Inhibits the Generation and Suppressive Effects of T Regulatory Cells.
Sukumar S, Wilson DC, Yu Y, Wong J, Naravula S, Ermakov G, Riener R, Bhagwat B, Necheva AS, Grein J, Churakova T, Mangadu R, Georgiev P, Manfra D, Pinheiro EM, Sriram V, Bailey WJ, Herzyk D, McClanahan TK, Willingham A, Beebe AM, Sadekova S. Sukumar S, et al. Among authors: willingham a. Cancer Res. 2017 Aug 15;77(16):4378-4388. doi: 10.1158/0008-5472.CAN-16-1439. Epub 2017 Jun 13. Cancer Res. 2017. PMID: 28611044
Establishment of engineered cell-based assays mediating LAG3 and PD1 immune suppression enables potency measurement of blocking antibodies and assessment of signal transduction.
Bhagwat B, Cherwinski H, Sathe M, Seghezzi W, McClanahan TK, de Waal Malefyt R, Willingham A. Bhagwat B, et al. Among authors: willingham a. J Immunol Methods. 2018 May;456:7-14. doi: 10.1016/j.jim.2018.02.003. Epub 2018 Feb 8. J Immunol Methods. 2018. PMID: 29427592 Free article.
Analysis of acyclic nucleoside modifications in siRNAs finds sensitivity at position 1 that is restored by 5'-terminal phosphorylation both in vitro and in vivo.
Kenski DM, Cooper AJ, Li JJ, Willingham AT, Haringsma HJ, Young TA, Kuklin NA, Jones JJ, Cancilla MT, McMasters DR, Mathur M, Sachs AB, Flanagan WM. Kenski DM, et al. Among authors: willingham at. Nucleic Acids Res. 2010 Jan;38(2):660-71. doi: 10.1093/nar/gkp913. Epub 2009 Nov 16. Nucleic Acids Res. 2010. PMID: 19917641 Free PMC article.
Single-stranded microRNA mimics.
Chorn G, Klein-McDowell M, Zhao L, Saunders MA, Flanagan WM, Willingham AT, Lim LP. Chorn G, et al. Among authors: willingham at. RNA. 2012 Oct;18(10):1796-804. doi: 10.1261/rna.031278.111. Epub 2012 Aug 21. RNA. 2012. PMID: 22912485 Free PMC article.
siRNA-optimized Modifications for Enhanced In Vivo Activity.
Kenski DM, Butora G, Willingham AT, Cooper AJ, Fu W, Qi N, Soriano F, Davies IW, Flanagan WM. Kenski DM, et al. Mol Ther Nucleic Acids. 2012 Jan 24;1(1):e5. doi: 10.1038/mtna.2011.4. Mol Ther Nucleic Acids. 2012. PMID: 23344622 Free PMC article.
151 results